MammaPrint diagnostic data

Agendia reported five-year follow-up data from the prospective Dutch RASTER observational study in 427 women with primary breast carcinoma showing that use of Agendia's MammaPrint in addition to standard guidelines used to select patients for adjuvant systemic therapy could lead to a 20% reduction in the use of adjuvant chemotherapy vs. standard guidelines alone. Specifically, MammaPrint classified 51% and 49% of patients as "low risk" and "high risk" for breast cancer recurrence, respectively, vs. 31% and 69% as determined by Adjuvant! Online, a web-based tool to help guide treatment decisions about chemotherapy use. Five-year distant metastasis-free survival (DMFS) in patients classified as "low risk" and "high risk" for breast cancer recurrence by MammaPrint was 96.1% and 89.8%, respectively. The 5-year DMFS for patients classified as "low risk" and "high risk" as determined by Adjuvant! Online was 94.4% and 92.4%, respectively.

In the study, tumor samples were collected from patients within 1 hour of surgery and were subsequently analyzed using MammaPrint's 70-gene prognosis signature. Patients with a "low risk" signature could be spared adjuvant systemic treatment, while patients with a "high risk" signature were considered for adjuvant systemic treatment. Agendia said the "vast majority" of patients classified as "high risk" by MammaPrint received chemotherapy. Data were presented at the European Breast Cancer meeting in Vienna. Agendia markets MammaPrint to assess the risk of breast cancer recurrence. ...